- Hikma’s first-half revenue amounted to $1.66 billion, slightly above the estimate of $1.65 billion.
- Revenue from injectables was $683 million, surpassing the estimate of $670.5 million.
- Branded revenue was reported at $437 million, just below the estimate of $437.7 million.
- Core operating profit totaled $373 million, close to the expected $373.5 million.
- Core EBITDA was $429 million, slightly lower than the anticipated $441.5 million.
- Core net income was $270 million.
- Core gross margin was 43.7%, falling short of the 46% estimate.
- Basic core earnings per share (EPS) were $1.22, exceeding the projection of $1.15.
- An interim dividend of 36 cents per share was announced.
- The company acknowledges lower core operating profit due to a strong 2024 comparison and product mix changes but expects growth in the second half of 2025.
- The full-year guidance for 2025 has been reiterated with confidence.
- Market sentiment includes 10 buy ratings, 3 hold ratings, and no sell ratings for Hikma.
A look at Hikma Pharmaceuticals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
With a solid Smartkarma Smart Score of 3 across key factors such as Value, Dividend, Resilience, and Momentum, Hikma Pharmaceuticals emerges as a promising player in the pharmaceutical industry. The company’s growth score of 4 reflects its potential for expanding its market presence and profitability in the long run. Hikma Pharmaceuticals, a multinational pharmaceutical group, has positioned itself to capitalize on opportunities in both branded and non-branded generic pharmaceutical products. Operating in key regions like the United States, the Middle East, North Africa, and Europe, the company demonstrates resilience and consistent momentum in its operations.
Overall, Hikma Pharmaceuticals showcases a balanced outlook across crucial factors, indicating stability and growth prospects for the company moving forward. With a strategy focused on developing, manufacturing, and marketing a diverse range of pharmaceutical products, Hikma Pharmaceuticals is well-positioned to navigate the competitive landscape and capture new opportunities in the global healthcare market. Investors may consider the company as a viable long-term investment option given its established presence and positive outlook across key performance indicators.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
